Manufacturer
ELI LILLY AND COMPANY
Contents
Ixekizumab
Indication
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ methotrexate for active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 disease-modifying anti-rheumatic drug therapies.
Instruction
SC Plaque psoriasis Recommended dose: 2 inj at wk 0, then 1 inj at wk 2, 4, 6, 8, 10 & 12. Maintenance dose: 1 inj every 4 wk. Psoriatic arthritis Recommended dose: 2 inj at wk 0, then 1 inj every 4 wk thereafter.
Drug interaction
CYP450 substrates w/ narrow therapeutic index eg, warfarin.
Malaysia
